1
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Does Treatment Influence Mortality in Depressives?: A Follow-up of 1076 Patients with Major Affective Disorders

, , , &
Pages 165-173 | Received 28 Jul 1989, Published online: 04 Dec 2011
 

Abstract

This article reports mortality risk among 1076 Iowans with major affective disorders (705 primary unipolar, 219 secondary unipolar, and 152 bipolar depressives) compared to that of the general population. Patients were divided into four treatment groups depending on primary mode of therapy during the index admission; the groups included electroconvulsive therapy (ECT), adequate antidepressants, inadequate antidepressants, and neither treatment. All patients in the sample had an increased risk for an early death. A high risk for suicide was found for patients within each individual treatment group during the follow-up, especially the first 2 years when 69.4% (n = 25) of total suicides occurred. There were no significant differences in the risk for suicides, or deaths from all causes combined, among patients in the four treatment groups. Furthermore, mortality did not differ between patients having a lifetime history of ECT and patients never having had ECT. We conclude from a short-term follow-up of depressives that mode of therapy received in the hospital has minimal influence on subsequent mortality, including suicide.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.